Skip to main content

Mission BioCapital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

62
Companies
$2.7B
Total invested
$51.3M
Avg. check
13
Industries
Biotechnology 21Therapeutics 14Health Care 13Medical 10Pharmaceutical 3Life Science 3+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 62
Sensorium Therapeutics
August 2025

Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.

Health Care · Boston$25.0M Series A
Shape Therapeutics
July 2026

A biotechnology company developing RNA technologies to shape the future of gene therapy

Biotechnology · Seattle$112.0M Grant
Invenio Imaging
June 2023

INVENIO IMAGING is a privately held corporation

Bioinformatics · Menlo ParkNon-equity Assistance
Deck Bio
April 2026

Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.

Biotechnology · Cambridge$3.1M Seed
March Biosciences
April 2025

March Biosciences is a clinical-stage cell therapy company that develops CAR-T cell strategies to address hematological cancers.

Biotechnology · Houston$200K Grant
Beech Biotech
April 2026

Beech Biotech is utilizing cutting-edge biology to develop innovative therapies for preeclampsia and other pregnancy-related issues.

Biotechnology · Lausanne$500K Seed
Glycomine
April 2025

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

Biotechnology · San Carlos$115.0M Series C
TippingPoint Biosciences
March 2026

TippingPoint Biosciences is developing therapeutics that target genome packaging states in diseases like cancer.

Biotechnology · San Francisco$4.5M Seed
Umlaut.Bio
February 2026

Umlaut.Bio is a spinout of the EMBL, is pursuing tRNA targets for treatment of cancer and immunological diseases.

Heidelberg$3.5M Pre-Seed
D2B3
April 2025

D2B3is a pre-clinical biotechnology startup dedicated to creating innovative drug delivery technologies for the brain.

Biotechnology · New Haven$500K Pre-Seed
Vivace Therapeutics
March 2025

Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.

Biotechnology · San Mateo$35.0M Series D
AmbAgon Therapeutics
February 2025

AmbAgon Therapeutics is a developer of cancer molecule therapeutics.

Biotechnology · San Francisco$5.0M Venture - Series Unknown
Tune Therapeutics
January 2025

Tune Therapeutics is an epigenetic programming platform for the treatment of disease.

Biotechnology · Durham$175.0M Series B
Alessa Therapeutics
December 2024

Alessa Therapeutics develops localized treatments for solid organ disease.

Biotechnology · San Francisco$15.0M Seed
Nuvig Therapeutics
December 2024

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

Biotechnology · Redwood City$161.0M Series B
Jupiter BioVentures
November 2024

Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.

Biotechnology · Delaware City$70.0M Venture - Series Unknown
Integrated Biosciences
October 2024

Integrated Biosciences develops next-generation therapeutics.

Biopharma · Redwood City$17.2M Seed
ImmunOs Therapeutics
September 2024

ImmunOs Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Schlieren$11.0M Series C
Progentos Therapeutics
May 2024

Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.

Life Science · Watertown$65.0M Series A
Nocion Therapeutics
March 2024

Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.

Biotechnology · Cambridge$62.0M Series B
Mediar Therapeutics
March 2023

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.

Biotechnology · Cambridge$85.0M Series A
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
Enodia Therapeutics
January 2026

Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases.

Biotechnology · Paris$24.2M Seed
AI Proteins
November 2025

AI Proteins is a biotechnology company that focuses on the de novo design and engineering of miniprotein therapeutics.

Artificial Intelligence (AI) · Boston$41.5M Series A

Where Mission BioCapital invests

Biotechnology21
Therapeutics14
Health Care13
Medical10
Pharmaceutical3
Life Science3

About Mission BioCapital's portfolio

How many companies has Mission BioCapital invested in?

Mission BioCapital has invested in 62 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Mission BioCapital invest in?

Mission BioCapital's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Pharmaceutical. The firm invests across 13 different industry categories.

What is Mission BioCapital's largest investment?

Among tracked funding rounds, Tune Therapeutics received $175.0M in a Series B round. Mission BioCapital's total known invested capital is $2.7B.

What is the average investment size for Mission BioCapital?

Mission BioCapital's average investment size is $51.3M across its portfolio of 62 companies.

What are Mission BioCapital's most recent investments?

Recent Mission BioCapital portfolio additions include Sensorium Therapeutics, Shape Therapeutics, Invenio Imaging, Deck Bio, March Biosciences. These companies were founded in 2020 or later.

Reach the founders behind these 62 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →